论文部分内容阅读
随着分子生物学技术的进步和在分子水平上对恶性肿瘤发病机制认识的不断加深,以细胞受体、表面抗原、关键基因和细胞内调控分子为靶点的分子靶向治疗已成为辅助传统治疗的合理选择。抗体导向治疗是一种新颖的分子靶向治疗手段。目前已研发多种抗体导向类抗癌药物,这类药物由特异性识别肿瘤细胞的靶向部分和杀伤肿瘤的效应部分组成,因而具有较强的靶向杀伤肿瘤细胞作用,同时可有效降低药物对局部正常组织和全身的系统性毒性作用。利用基因工程技术将人类血清可溶性肿瘤坏死因子相关凋亡诱导配体(serum-soluble TNF-related apoptosis-inducing ligand,sTRAIL)与抗肿瘤单链抗体(single chain antibody fragment,scFv)融合,构建scFv-sTRAIL融合蛋白,是一种理想的抗体导向治疗策略。通过scFv与肿瘤细胞所特有的细胞表面抗原的特异结合,加强sTRAIL在肿瘤病灶的富集,靶向诱导肿瘤细胞凋亡,从而获得增强抗体的疗效和更高的药物安全性。
With advances in molecular biology techniques and increasing awareness of the pathogenesis of malignant tumors at the molecular level, molecular targeted therapy targeting cellular receptors, surface antigens, key genes and intracellular regulatory molecules has become an auxiliary tradition A reasonable choice of treatment. Antibody-directed therapy is a novel molecular targeted therapy. At present, a variety of antibody-directed anti-cancer drugs have been developed. These drugs are composed of a target moiety that specifically recognizes tumor cells and an anti-tumor effect moiety that has a strong target for killing tumor cells while effectively reducing drug Systematic toxic effects on local, normal tissue and whole body. Human serum soluble TNF-related apoptosis-inducing ligand (sTRAIL) was fused with single chain antibody fragment (scFv) using gene engineering technology to construct scFv- sTRAIL fusion protein, is an ideal antibody-directed therapeutic strategy. The specific binding of scFv to cell surface antigens unique to tumor cells enhances the enrichment of sTRAIL in tumor lesions and targets the induction of tumor cell apoptosis so as to obtain enhanced antibody efficacy and higher drug safety.